Denali Therapeutics, Inc. (DNLI)
24.20
-0.72
(-2.89%)
USD |
NASDAQ |
Aug 24, 16:00
23.73
-0.47
(-1.94%)
After-Hours: 20:00
Denali Therapeutics Total Liabilities (Quarterly) : 322.78M for June 30, 2026
Total Liabilities (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 322.78M |
| March 31, 2026 | 339.92M |
| December 31, 2025 | 131.09M |
| September 30, 2025 | 129.42M |
| June 30, 2025 | 139.19M |
| March 31, 2025 | 148.66M |
| December 31, 2024 | 144.50M |
| September 30, 2024 | 135.52M |
| June 30, 2024 | 115.51M |
| March 31, 2024 | 125.62M |
| December 31, 2023 | 122.96M |
| September 30, 2023 | 118.45M |
| June 30, 2023 | 118.91M |
| March 31, 2023 | 442.64M |
| December 31, 2022 | 417.81M |
| September 30, 2022 | 416.30M |
| June 30, 2022 | 408.01M |
| March 31, 2022 | 402.93M |
| December 31, 2021 | 441.87M |
| September 30, 2021 | 437.69M |
| Date | Value |
|---|---|
| June 30, 2021 | 437.11M |
| March 31, 2021 | 442.50M |
| December 31, 2020 | 453.75M |
| September 30, 2020 | 187.76M |
| June 30, 2020 | 145.17M |
| March 31, 2020 | 150.55M |
| December 31, 2019 | 158.34M |
| September 30, 2019 | 164.78M |
| June 30, 2019 | 162.43M |
| March 31, 2019 | 159.95M |
| December 31, 2018 | 115.14M |
| September 30, 2018 | 83.30M |
| June 30, 2018 | 81.78M |
| March 31, 2018 | 74.92M |
| December 31, 2017 | 20.92M |
| September 30, 2017 | 17.17M |
| June 30, 2017 | |
| March 31, 2017 | |
| December 31, 2016 | 16.55M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 1.646B |
| Biogen, Inc. | 13.24B |
| Oncolytics Biotech, Inc. | 13.84M |
| Sangamo Therapeutics, Inc. | 78.92M |
| Sarepta Therapeutics, Inc. | 1.661B |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 1.158B |
| Shareholders Equity (Quarterly) | 835.18M |
| Debt to Equity Ratio | 0.0451 |
| Current Ratio | 8.369 |
| Net Debt Paydown Yield | 0.05% |